Status:
COMPLETED
Role of Montelukast in Asthma and Allergic Rhinitis Patients
Lead Sponsor:
Clinision
Conditions:
Asthma and Allergic Rhinitis
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
To determine the effect of Montelukast in Asthma and Allergic rhinits patients
Detailed Description
Montelukast is a potent and selective blocker of the CysLT1 receptor. Accordingly, a recent study has shown that Montelukast can improve symptoms of seasonal allergic rhinitis and asthma in patients w...
Eligibility Criteria
Inclusion
- Age \>18 years
- Signed Informed Consent
- Clinical diagnosis of Asthma and Allergic Rhinitis
Exclusion
- Previous adverse reaction to Montelukast
- History of hyper-eosinophilic disorder other than atopic disease
- Female subjects who are pregnant, breast-feeding
- Any significant and active pulmonary pathology other than asthma
Key Trial Info
Start Date :
August 28 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2019
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT03380975
Start Date
August 28 2018
End Date
June 30 2019
Last Update
January 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Faisal Faiyaz Zuberi
Karachi, Sindh, Pakistan